Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, HealthCare Global Enterprises's average EBITDA Per Share Growth Rate was 5.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 38.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of HealthCare Global Enterprises was 89.40% per year. The lowest was -38.90% per year. And the median was 9.70% per year.
HealthCare Global Enterprises (NSE:HCG) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
HealthCare Global Enterprises 5-Year EBITDA Growth Rate Related Terms
NSE:HCG vs HCA, THC, EHC: 5-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, HealthCare Global Enterprises's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthCare Global Enterprises 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthCare Global Enterprises's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where HealthCare Global Enterprises's 5-Year EBITDA Growth Rate falls into.
HealthCare Global Enterprises 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 38.60% mean?
HealthCare Global Enterprises (NSE:HCG) has a 5-Year EBITDA Growth Rate of 38.60% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for HealthCare Global Enterprises and its competitors.
Is HealthCare Global Enterprises' 5-Year EBITDA Growth Rate too high?
HealthCare Global Enterprises' current 5-Year EBITDA Growth Rate is 38.60%. Overall, HealthCare Global Enterprises has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HealthCare Global Enterprises' 5-Year EBITDA Growth Rate compare to HCA and THC?
HealthCare Global Enterprises' 5-Year EBITDA Growth Rate of 38.60% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for HealthCare Global Enterprises and its competitors. HealthCare Global Enterprises's current 5-Year EBITDA Growth Rate is 38.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthCare Global Enterprises stock overvalued right now?
Based on GuruFocus' analysis, HealthCare Global Enterprises (NSE:HCG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹607.17, compared to a current price of ₹674.15 — trading 11% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 38.60%. HealthCare Global Enterprises' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For HealthCare Global Enterprises (NSE:HCG), the current 5-Year EBITDA Growth Rate is 38.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthCare Global Enterprises (NSE:HCG) Overvalued in 2026?
Based on GuruFocus' analysis, HealthCare Global Enterprises stock appears to be overvalued.
The current stock price of ₹674.15 is trading 11% above its estimated GF Value™ of ₹607.17.
GuruFocus considers HealthCare Global Enterprises to be Modestly Overvalued.
Key valuation signals for NSE:HCG:
5-Year EBITDA Growth Rate: 38.60%
GF Value™: ₹607.17 vs. price of ₹674.15 (11% above fair value)
No single metric tells the full story. See the NSE:HCG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
81GF Score
Get the complete analysis for NSE:HCG
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HCG has been successfully added to your 
